Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
02:13am, Thursday, 01'st Jan 2026
Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 week
In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s
03:08pm, Wednesday, 31'st Dec 2025
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
09:20am, Tuesday, 30'th Dec 2025
Kelowna, British Columbia – December 30, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, pr
GLP-1 weight-loss pills set to reshape US food demand in 2026
09:21am, Wednesday, 24'th Dec 2025
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in Jan
US health agency to expand access to GLP-1 weight-loss drugs
04:56pm, Tuesday, 23'rd Dec 2025
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
12:06pm, Tuesday, 23'rd Dec 2025
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms r
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
11:16am, Tuesday, 23'rd Dec 2025
CNBC's Annika Kim Constantino reports on the FDA's approval of the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk.
Novo Nordisk Stock Soars on FDA-Cleared GLP-1 Pill
10:38am, Tuesday, 23'rd Dec 2025
Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from the U.S. Food & Drug Administration (FDA) for the first ever GLP
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
09:29am, Tuesday, 23'rd Dec 2025
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings c
Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
03:02am, Tuesday, 23'rd Dec 2025
The FDA on Monday approved the first-ever GLP-1 pill from Novo Nordisk. The approval gives the Danish pharma giant a head start against U.S. rival Eli Lilly.
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug
06:44pm, Monday, 22'nd Dec 2025
The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.
FDA approves first GLP-1 pill for obesity from Novo Nordisk
06:09pm, Monday, 22'nd Dec 2025
FDA approves first GLP-1 pill for obesity from Novo Nordisk
The FDA has approved the first GLP-1 pill for weight loss, clearing a tablet from Novo Nordisk
06:05pm, Monday, 22'nd Dec 2025
Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
07:30am, Thursday, 18'th Dec 2025
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telo
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switch
